Efficacy of Vyepti highlighted by new clinical trial

New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for patients severely impacted by migraine, with the placebo-controlled Phase IV trial finding that patients with chronic migraine and medication-overuse headache rapidly benefit from treatment with Vyepti, Danish biopharma company Lundbeck (CPH: LUN) today revealed.

This trial randomized 608 patients with a dual diagnosis of chronic migraine (CM) and medication-overuse headache (MOH) to receive an infusion of either Vyepti 100 mg or placebo. The RESOLUTION trial evaluated the efficacy of Vyepti versus placebo as add-on to a brief educational intervention for the prevention of migraine. Vyepti met the primary endpoint, showing statistically-significant greater monthly migraine day (MMD) reductions during weeks 1 to 4 with Vyepti, compared to placebo. From a baseline average of 21 days, the change from baseline in MMDs were -6.9 with Vyepti treatment compared to -3.7 days for placebo (p<0.0001).

Confirmed early onset of Vyepti’s efficacy